TWEAK and Fn14: New molecular targets for cancer therapy?

被引:58
作者
Winkles, JA
Tran, NL
Berens, ME
机构
[1] Univ Maryland, Sch Med, Dept Surg, Baltimore, MD 21201 USA
[2] Univ Maryland, Sch Med, Dept Physiol, Baltimore, MD 21201 USA
[3] Univ Maryland, Sch Med, Greenebaum Canc Ctr, Baltimore, MD 21201 USA
[4] Translat Genom Res Inst, Neurogenom Div, Phoenix, AZ 85004 USA
关键词
TNF; TWEAK; Fn14; cancer tumor; endothelial cell; angiogenesis;
D O I
10.1016/j.canlet.2005.03.048
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Tumor necrosis factor-like weak inducer of apoptosis (TWEAK) is a member of the tumor necrosis factor (TNF) superfamily of structurally related cytokines. Full-length, membrane-anchored TWEAK can be found on the surface of many cell types and a smaller, biologically active form, generated via proteolytic processing, has also been detected in the extracellular milieu. TWEAK acts via binding to a recently identified TNF receptor superfamily member named fibroblast growth factor-inducible 14 (Fn14). It has been demonstrated that TWEAK binding to the Fn14 receptor, or constitutive Fn14 overexpression, activates the nuclear factor-KB signaling pathway, which is known to play an important role in immune and inflammatory processes, oncogenesis, and cancer therapy resistance. In this article, we review recent studies indicating that TWEAK and Fn14 may be potential regulators of human tumorigenesis. (c) 2005 Elsevier Ireland Ltd. All rights reserved.
引用
收藏
页码:11 / 17
页数:7
相关论文
共 42 条
[1]   Tumorigenesis and the angiogenic switch [J].
Bergers, G ;
Benjamin, LE .
NATURE REVIEWS CANCER, 2003, 3 (06) :401-410
[2]   The Fn14 cytoplasmic tall binds tumour-necrosis-factor-receptor-associated factors 1, 2, 3 and 5 and mediates nuclear factor-κB activation [J].
Brown, SAN ;
Richards, CM ;
Hanscom, HN ;
Feng, SLY ;
Winkles, JA .
BIOCHEMICAL JOURNAL, 2003, 371 :395-403
[3]   The role of TWEAK/Fn14 in the pathogenesis of inflammation and systemic autoimmunity [J].
Campbell, S ;
Michaelson, J ;
Burkly, L ;
Putterman, C .
FRONTIERS IN BIOSCIENCE-LANDMARK, 2004, 9 :2273-2284
[4]   Antiangiogenic cancer therapy [J].
Cao, YH .
SEMINARS IN CANCER BIOLOGY, 2004, 14 (02) :139-145
[5]   TWEAK, a new secreted ligand in the tumor necrosis factor family that weakly induces apoptosis [J].
Chicheportiche, Y ;
Bourdon, PR ;
Xu, HD ;
Hsu, YM ;
Scott, H ;
Hession, C ;
Garcia, I ;
Browning, JL .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1997, 272 (51) :32401-32410
[6]   Proinflammatory activity of TWEAK on human dermal fibroblasts and synoviocytes: blocking and enhancing effects of anti-TWEAK monoclonal antibodies [J].
Chicheportiche, Y ;
Chicheportiche, R ;
Sizing, I ;
Thompson, J ;
Benjamin, CB ;
Ambrose, C ;
Dayer, JM .
ARTHRITIS RESEARCH, 2002, 4 (02) :126-133
[7]   Down-regulated expression of TWEAK mRNA in acute and chronic inflammatory pathologies [J].
Chicheportiche, Y ;
Fossati-Jimack, L ;
Moll, S ;
Ibnou-Zekri, N ;
Izui, S .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2000, 279 (01) :162-165
[8]   TWEAK is expressed by glial cells, induces astrocyte proliferation and increases EAE severity [J].
Desplat-Jégo, S ;
Varriale, S ;
Creidy, R ;
Terra, R ;
Bernard, D ;
Khrestchatisky, M ;
Izui, S ;
Chicheportiche, Y ;
Boucraut, J .
JOURNAL OF NEUROIMMUNOLOGY, 2002, 133 (1-2) :116-123
[9]   TWEAK is an endothelial cell growth and chemotactic factor that also potentiates FGF-2 and VEGF-A mitogenic activity [J].
Donohue, PJ ;
Richards, CM ;
Brown, SAN ;
Hanscom, HN ;
Buschman, J ;
Thangada, S ;
Hla, T ;
Williams, MS ;
Winkles, JA .
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2003, 23 (04) :594-600
[10]   The Fn14 immediate-early response gene is induced during liver regeneration and highly expressed in both human and murine hepatocellular carcinomas [J].
Feng, SLY ;
Guo, Y ;
Factor, VM ;
Thorgeirsson, SS ;
Bell, DW ;
Testa, JR ;
Peifley, KA ;
Winkles, JA .
AMERICAN JOURNAL OF PATHOLOGY, 2000, 156 (04) :1253-1261